HUP0400564A2 - Cianoguanidin prodrugok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Cianoguanidin prodrugok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0400564A2
HUP0400564A2 HU0400564A HUP0400564A HUP0400564A2 HU P0400564 A2 HUP0400564 A2 HU P0400564A2 HU 0400564 A HU0400564 A HU 0400564A HU P0400564 A HUP0400564 A HU P0400564A HU P0400564 A2 HUP0400564 A2 HU P0400564A2
Authority
HU
Hungary
Prior art keywords
group
straight
optionally substituted
hydrocarbon group
independently
Prior art date
Application number
HU0400564A
Other languages
English (en)
Inventor
Ernst Torndal Binderup
Pernille-Julia Vig Hjarnaa
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of HUP0400564A2 publication Critical patent/HUP0400564A2/hu
Publication of HUP0400564A3 publication Critical patent/HUP0400564A3/hu
Publication of HU230544B1 publication Critical patent/HU230544B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

A találmány tárgya (I) általános képletű vegyületek - ahol X1 és X2jelentése egymástól függetlenül vegyértékvonal, egyenes, elágazó láncúés/vagy ciklusos, kétértékű szénhidrogén-csoport, amely adott esetbenszubsztituált; hetero-arilén- vagy nem aromás heterociklusos kétértékűszénhidrogén-csoport, melyek mindegyike adott esetben előbbiek közöttegy vagy több egyenes, elágazó láncú és/vagy ciklusos, nem aromásszénhidrogén-csoporttal szubsztituált, Y1 és Y2 jelentése egymástólfüggetlenül vegyértékvonal, R'-O-R'' képletű kétértékű étercsoport,R'-N-R'' képletű kétértékű amincsoport, O, S, S(O), S(O)2, C(O), NH-CO, CO-NH, SO2-N(R'), metilén- vagy N(R')-SO2 csoport, ahol R' és R''jelentése egymástól függetlenül egyenes vagy elágazó láncú, legfeljebb4 szénatomos, kétértékű szénhidrogén-csoport; Y3 jelentése O, O-C(O),C(O)-O, N(R8), ahol R8 jelentése hidrogénatom vagy 1-4 szénatomosalkilcsoport; R1 jelentése hidrogénatom vagy egyenes, elágazó láncúés/vagy ciklusos alkilcsoport, amely adott esetben fenilcsoporttalszubsztituált; vagy aromás szénhidrogén-csoport; R2 jelentése adottesetben szubsztituált aril-, heteroaril- vagy nem aromásheterociklusos szénhidrogén-csoport, tetrahidropiranil-oxi-, di-(1-4szénatomos alkoxi)-foszfinoiloxi- vagy (1-4 szénatomos alkoxi)-karbonil-amino-csoport; R3 jelentése hidrogénatom, egyenes, elágazóláncú és/vagy ciklusos szénhidrogén-csoport, amely adott esetbenhelyettesítve lehet, heteroaril- vagy nem aromás heterociklusosszénhidrogén-csoport, melyek mindegyike adott esetben szubsztituáltegy vagy több egyenes, elágazó láncú és/vagy ciklusos szénhidrogén-csoporttal; (a) képletű csoport; ahol s értéke 1-200 közötti egészszám; R6 jelentése hidrogénatom vagy adott esetben szubsztituált, nemaromás szénhidrogén-csoport; R7 jelentése egymástól függetlenülhidrogénatom vagy metilcsoport; R4 és R5 jelentése egymástólfüggetlenül hidrogénatom, egyenes, elágazó láncú és/vagy ciklusosszénhidrogén-csoport, amely adott esetben halogénatommal, hidroxil-,amino-, nitro- vagy cianocsoporttal szubsztituált; A jelentésehidrogénatom, adott esetben szubsztituált egyenes, elágazó láncúés/vagy ciklusos szénhidrogén-csoport, hidroxilcsoport, halogénatom,nitro-, ciano-, heteroaril-, heteroaralkil- vagy tiolcsoport; m és rértéke egymástól függetlenül 0-4 közötti egész szám, és n értéke 0vagy 1 ; Z' jelentése gyógyászatilag elfogadható anion, pl. klorid,bromid, jodid, szulfát, metánszulfonát, para-toluolszulfonát, nitrátvagy foszfát. A vegyületek prodrugként alkalmazhatók a humán ésállatgyógyászatban. Ó
HU0400564A 2000-11-21 2001-11-14 Cianoguanidin prodrugok HU230544B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25207800P 2000-11-21 2000-11-21
US60/252,078 2000-11-21
PCT/DK2001/000750 WO2002042265A2 (en) 2000-11-21 2001-11-14 Cyanoguanidine prodrugs

Publications (3)

Publication Number Publication Date
HUP0400564A2 true HUP0400564A2 (hu) 2004-06-28
HUP0400564A3 HUP0400564A3 (en) 2008-03-28
HU230544B1 HU230544B1 (hu) 2016-11-28

Family

ID=22954502

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400564A HU230544B1 (hu) 2000-11-21 2001-11-14 Cianoguanidin prodrugok

Country Status (17)

Country Link
US (1) US6525077B2 (hu)
EP (2) EP2894149B1 (hu)
JP (1) JP4521157B2 (hu)
KR (1) KR100871577B1 (hu)
CN (1) CN100368401C (hu)
AU (3) AU1494702A (hu)
BR (1) BR0115514A (hu)
CA (1) CA2426601C (hu)
CZ (1) CZ305764B6 (hu)
ES (2) ES2643083T3 (hu)
HK (2) HK1073297A1 (hu)
HU (1) HU230544B1 (hu)
IL (2) IL155483A0 (hu)
MX (1) MXPA03004394A (hu)
PL (1) PL224371B1 (hu)
RU (1) RU2312858C2 (hu)
WO (2) WO2002042265A2 (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
CN1662502A (zh) * 2002-05-17 2005-08-31 利奥制药有限公司 氰基胍前药
ES2290454T3 (es) * 2002-05-17 2008-02-16 Leo Pharma A/S Profarmacos de cianoguanidina.
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
JP2006523237A (ja) * 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ, インコーポレイテッド Pi−3キナーゼインヒビタープロドラッグ
EP1838696B1 (en) 2004-12-22 2016-03-09 Leo Pharma A/S Novel cyanoguanidine compounds
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
US8173677B2 (en) * 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
WO2009072004A2 (en) * 2007-09-26 2009-06-11 Gemin X Pharmaceuticals Canada, Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
US8101606B2 (en) 2007-11-12 2012-01-24 Washington University Neurofibromin pathway modulators
JP5688367B2 (ja) 2008-08-29 2015-03-25 トポターゲット・アクティーゼルスカブTopoTarget A/S 新規なウレアおよびチオウレア誘導体
WO2010088842A1 (zh) 2009-02-06 2010-08-12 天津和美生物技术有限公司 含有吡啶基氰基胍的药物组合物及其制备和应用
US20120270900A1 (en) 2009-07-17 2012-10-25 Topo Target A/S Novel method of treatment
US9224007B2 (en) * 2009-09-15 2015-12-29 International Business Machines Corporation Search engine with privacy protection
US9600134B2 (en) 2009-12-29 2017-03-21 International Business Machines Corporation Selecting portions of computer-accessible documents for post-selection processing
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
US9676721B2 (en) 2010-09-03 2017-06-13 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
CN103607888A (zh) * 2011-04-08 2014-02-26 斯法尔制药私人有限公司 取代的甲基甲酰基试剂以及使用所述试剂改进化合物的物理化学性质和/或药代动力学性质的方法
US9195853B2 (en) 2012-01-15 2015-11-24 International Business Machines Corporation Automated document redaction
JP2015521603A (ja) * 2012-06-15 2015-07-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 脳癌の新規治療薬
CN104768931A (zh) * 2012-06-27 2015-07-08 向日葵研究有限责任公司(美国) 化合物及其治疗用途
AU2013326850B2 (en) 2012-10-04 2017-09-21 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
US9892278B2 (en) 2012-11-14 2018-02-13 International Business Machines Corporation Focused personal identifying information redaction
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
US20200138964A1 (en) * 2017-04-25 2020-05-07 Seikagaku Corporation Tertiary amine compound or imine compound-polymer conjugate and production method therefor
EP3590927A1 (en) * 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
US11174229B2 (en) 2018-10-29 2021-11-16 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501103A (ja) * 1989-06-26 1993-03-04 ザ・リサーチ・ファウンデーション・オヴ・ステイト・ユニヴァーシティ・オヴ・ニューヨーク ビス―アシルオキシメチル誘導体
GB9219472D0 (en) 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711124D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711119D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711123D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
AU4076500A (en) * 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. (n)-substituted cyanoguanidine compounds
WO2000061561A1 (en) 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Cyanoguanidine compounds

Also Published As

Publication number Publication date
HK1073297A1 (en) 2005-09-30
ES2549260T3 (es) 2015-10-26
CN1589262A (zh) 2005-03-02
CZ20031303A3 (en) 2004-04-14
JP4521157B2 (ja) 2010-08-11
RU2312858C2 (ru) 2007-12-20
HU230544B1 (hu) 2016-11-28
ES2643083T3 (es) 2017-11-21
EP2894149A1 (en) 2015-07-15
WO2002042276A1 (en) 2002-05-30
KR20030051861A (ko) 2003-06-25
CZ305764B6 (cs) 2016-03-09
HUP0400564A3 (en) 2008-03-28
JP2004520282A (ja) 2004-07-08
EP1339686B1 (en) 2015-09-16
IL155483A0 (en) 2003-11-23
AU1494702A (en) 2002-06-03
AU2002223511A1 (en) 2002-06-03
EP1339686A2 (en) 2003-09-03
BR0115514A (pt) 2003-12-30
CA2426601A1 (en) 2002-05-30
AU2002214947B2 (en) 2007-02-15
PL362864A1 (en) 2004-11-02
KR100871577B1 (ko) 2008-12-02
IL155483A (en) 2010-12-30
WO2002042265A3 (en) 2002-08-15
HK1212678A1 (zh) 2016-06-17
US6525077B2 (en) 2003-02-25
CA2426601C (en) 2015-01-13
MXPA03004394A (es) 2004-04-20
PL224371B1 (pl) 2016-12-30
EP2894149B1 (en) 2017-08-02
CN100368401C (zh) 2008-02-13
WO2002042265A2 (en) 2002-05-30
US20020165201A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
HUP0400564A2 (hu) Cianoguanidin prodrugok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JO2644B1 (en) Derivatives of N- (amino-aryl mixture) -H1- indole-2-carboxamide Synthesis and therapeutic use
RS52326B (en) Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CY1112201T1 (el) Φαρμακο για τη θεραπευτικη αγωγη γριπης
HUP0104188A2 (hu) Antranilsav- és tioantranilsav-N-aril-amidok, előállításuk és alkalmazásuk VEGF receptor tirozinkináz inhibítorokként
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
CY1110986T1 (el) Αζολια ως αναστολεις της αποκαρβοξυλασης μηλονυλο-συνενζυμου α χρησιμα ως μεταβολικοι διαμορφωτες
NO20045369L (no) Nye, substituerte sulfamatanticonvulsivaderivater
BRPI0413991A (pt) composto ativador de ppar e composição farmacêutica contendo o mesmo
SE0202133D0 (sv) Novel compounds
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
RS54718B1 (en) 1,2,4-THIAZOLIDIN-3-DERIVATIVES AND THEIR USE IN CANCER TREATMENT
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CY1109331T1 (el) Παραγωγα αμινοφαινυλιου ως νεοι αναστολεις της αποακετυλασης ιστονης
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
AR068055A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol su procedimiento de preparacion su aplicacion como medicamentos composiciones farmaceuticas y su utilizacion principalmente como inhibidores de met
TW200612920A (en) Novel imidazolidine derivatives
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
UA86013C2 (ru) Производные арилалкилкарбаматов, их получение и применение в лечении
TW200612931A (en) Substituted biphenyl derivatives
ATE482933T1 (de) Sulfopyrrolderivate
TW200745048A (en) Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors
DE602004015277D1 (de) Substituierte-1-phthalazinamine als vr-1-antagonisten